Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel®) in paediatric patients

Dermatology

Volumn 215, Issue SUPPL. 1, 2007, Pages 3-17

  Eichenfield, Lawrence F ^a   Thaci, Diamant ^b   De Prost, Yves ^c   Puig, Lluis ^d   Paul, Carle ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Atopic eczema; Paediatrics; Pimecrolimus; Topical calcineurin inhibitor

Indexed keywords

PIMECROLIMUS; TACROLIMUS;

APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ATOPIC DERMATITIS; BRONCHITIS; CLINICAL TRIAL; CONJUNCTIVITIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EAR INFECTION; ENTEROBIASIS; ERYTHEMA; EXTERNAL OTITIS; FACE; FEVER; GASTROENTERITIS; GROWTH RETARDATION; HUMAN; INCIDENCE; INFLUENZA; LARYNGITIS; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; NECK; NONHUMAN; OTITIS MEDIA; PEDIATRICS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SKIN INFECTION; SKINFOLD; STAPHYLOCOCCUS AUREUS; TONSILLITIS; TRACHEITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANIMALS; BODY SIZE; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFECTION; SEVERITY OF ILLNESS INDEX; SKIN; SKIN DISEASES, INFECTIOUS; TACROLIMUS;

EID: 34948825255     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102116     Document Type: Review

References (61)

1. Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-876.
2. Lewis-Jones MS, Finlay AY, Dykes PJ: The Infants' Dermatitis Quality of Life Index. Br J Dermatol 2001;144:104-110.
3. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG: The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 1998;138:107-113.
4. Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-127.
5. Ricci, G., Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M: Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006;55:765-771.
6. Hill CJ, Rostenberg A, Jr.: Adverse effects from topical steroids. Cutis 1978;21:624-628.
7. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C: Cushing's syndrome after topical application of corticosteroids. Am J Dis Child 1982;136:274-275.
8. Bode HH: Dwarfism following long-term topical corticosteroid therapy. JAMA 1980;244:813-814.
9. Queille C, Pommarede R, Saurat JH: Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-253.
10. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-936.
11. Fischer G: Compliance problems in pediatric atopic eczema. Aust J Dermatol 1996;37(suppl 1):10-13.
12. Elidel (pimecrolimus) Prescribing Information. East Hanover, New Jersey, USA. Novartis Pharmaceuticals Corp. July 2004.
13. Protopic (tacrolimus) Product Information. Astellas Pharma US. Three Parkway North Deerfield, IL, USA July 2005.
14. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-273.
15. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-576.
16. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG: Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006;141:199-212.
17. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004;122:673-684.
18. Kalthoff F, Chung J, Musser P, Stuetz A: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133:350-359.
19. Billich A, Aschauer H, Aszodi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
20. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
21. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin ME, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-973.
22. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, Folster-Holst R, Potter P, Marshall K, Thurston M, Bush C, Cherill R: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-162.
23. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
24. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
25. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y: Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-284.
26. Papp KA, Werfel T, Folster-Holst R, Ortonne JP, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C: Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005;52:240-246.
27. Kaufmann R, Folster-Holst R, Hoger P, Thaci D, Loffler H, Staab D, Brautigam M: Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004;114:1183-1188.
28. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-18.
29. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, Eichenfield LF, Cherill R, Hanifin J: Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1,550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004;150:96-102.
30. Papp K, Staab D, Harper J, Potter P, Puig L, Ortonne JP, Molloy S, Barbier N, Paul C: Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol 2004;43:978-983.
31. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y: Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006;117:e118-e128.
32. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S, Abrams B: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004;51:515-525.
33. Paller AS, Lebwohl M, Fleischer AB, Jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-822.
34. Rystedt I, Strannegard IL, Strannegard O: Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol 1986;114:575-582.
35. Lubbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003;4:641-654.
36. David TJ, Cambridge GC: Bacterial infection and atopic eczema. Arch Dis Child 1986;61:20-23.
37. David TJ, Longson M: Herpes simplex infections in atopic eczema. Arch Dis Child 1985;60:338-343.
38. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-787.
39. Staab D, Pariser D, Gottlieb AB, Kaufmann R, Eichenfield LF, Langley RG, Scott G, Ebelin ME, Barilla D, Schmidli H, Burtin P: Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis - a multicenter, 3-week, open-label study. Pediatr Dermatol 2005;22:465-471.
40. Lakhanpaul M, Davies T, Allen B, Stephenson T, Scott G, Ebelin M: Pimecrolimus (SDZ ASM 981) cream 1%: minimal systemic absorption in infants with atopic dermatitis during long-term treatment. Ann Dermatol Venereol 2002;129:415.
41. Turpeinen M: Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988;118:517-522.
42. Papp K, Breuer K, Meurer M, Ortonne J, Potter P, de Prost Y, Davidson M, Barbier N, Goertz H, Paul C: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005;52:247-253.
43. Elidel (pimecrolimus) Cream 1% Safety Summary Children Population Food and Drug Administration Pediatric Advisory Committee Briefing Information.
44. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005;125:1020-1025.
45. Drug Regulatory Affairs: Elidel (pimecrolimus) cream 1%. NDA 21-302, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm.
46. Food and Drug Administration Pediatric Advisory Committee. Briefing Information. February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4089b2_03_04_Elidel%20Novartis%20Briefing%20Bookredacted.pdf. Accessed 16 January 2006.
47. Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G: Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int 1992;5(suppl 1):S454-S458.
48. Tran C, Lubbe J, Sorg O, Doelker L, Carraux P, Antille C, Grand D, Leemans E, Kaya G, Saurat JH: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211:341-347.
49. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ: The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23.
50. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CE: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-816.
51. Vermeer BJ, Heremans GF: A case of growth retardation and Cushing's syndrome due to excessive application of betamethasone-17-valerate ointment. Dermatologica 1974;149:299-304.
52. Preece MA: The effect of administered corticosteroids on the growth of children. Postgrad Med J 1976;52:625-630.
53. Weston WL, Sams WM Jr, Morris HG, Arthur JM, Blakeman GJ, Andresen M: Morning plasma cortisol levels in infants treated with topical fluorinated glucocorticosteroids. Pediatrics 1980;65:103-106.
54. Turpeinen M, Salo OP, Leisti S: Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
55. Eichenfield LF, Hanifin JM, Beck LA, Lemanske RF, Jr., Sampson HA, Weiss ST, Leung DY: Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003;111:608-616.
56. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T; European Academy of Allergology; Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969-987.
57. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T; European Academy of Allergology; Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
58. Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, Ocampo Candiani J, Cox M, Langeraar J, Simon JC: Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118:226-232.
59. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
60. Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R: New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006;118:3-21.
61. Beck LA, Leung DY: Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000;106:S258-S263.